Riskpilot← Back to searchSign inGet full accessRepolar Pharmaceuticals Oy
OYActiveY-tunnus 2012066-7Nihtisillantie 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20066 employeeswww.repolar.com
Revenue 2024
EUR 3,5M
+9% vs 2023
EBITDA margin
28.7%
-2% vs 2023
Equity ratio
77.0%
Financial strength
Net profit 2024
EUR 1,3M
+56% vs 2023
| Revenue | EUR 3,5M | +9% |
| EBITDA | EUR 1M | -2% |
| Net profit | EUR 1,3M | +56% |
| Total assets | EUR 1,7M | -50% |
| Equity | EUR 1,3M | -54% |
| Employees | 6 | — |
Legal name
Repolar Pharmaceuticals Oy
Y-tunnus number
2012066-7
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12. tammikuuta 2006
Share capital
EUR 52 800
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Yhtiön toimialana on lääketieteen, erityisesti haavan- ja ihonhoidon sekä tulehdusten ja kasvainten hoidon tutkimus ja kehitys sekä kosmetiikkatuotteiden tutkimus ja kehitys.
Address
Nihtisillantie 3
Phone
+358407171761
Email
info@repolar.com
Website
www.repolar.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 1 645 | 2 156 | 2 439 | 2 839 | 3 216 | 3 517 |
| Staff expenses | −397 | −408 | −365 | −471 | −385 | −448 |
| EBITDA | 400 | 691 | 542 | 879 | 1 037 | 1 011 |
| Depreciation & amort. | −16 | −15 | −14 | −120 | −65 | −49 |
| EBIT | 384 | 676 | 528 | 759 | 972 | 961 |
| Net financials | −0 | 0 | −0 | −1 | 40 | 621 |
| Profit before tax | 383 | 676 | 528 | 758 | 1 011 | 1 582 |
| Tax | 77 | 136 | 106 | 152 | 203 | 320 |
| Net profit | 306 | 541 | 422 | 606 | 809 | 1 262 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 1 318 | 1 722 | 2 104 | 2 734 | 3 487 | 1 739 |
| Equity | 1 086 | 1 540 | 1 839 | 2 298 | 2 923 | 1 339 |
| Long-term debt | — | — | — | — | 0 | 0 |
| Short-term debt | 232 | 182 | 265 | 436 | 564 | 399 |
| Total debt | 232 | 182 | 265 | 436 | 564 | 399 |
EBITDA margin
28.7%
This company
15.8%
Market median
+82% vs market
20192024
Equity ratio
77.0%
This company
38.2%
Market median
+102% vs market
20192024
Return on equity
94.2%
This company
18.4%
Market median
+412% vs market
20192024
Net profit margin
35.9%
This company
8.1%
Market median
+343% vs market
20192024
Asset turnover
2.02×
This company
1.12×
Market median
+80% vs market
20192024
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20192024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RJ Audit | Audit | 2006 | — | — |
PT Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
RO Deputy auditor | Deputy auditor | 2025 | — | — |
MO Deputy auditor | Deputy auditor | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairperson | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairperson | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
North Star Bidco Oy | Company | 65.2% | 65.2% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
North Star Bidco Oy
Repolar Pharmaceuticals Oy Board members of Repolar Pharmaceuticals Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Riku Juhani Kärnä | Audit | 0 companies |
| Paavo Tuomas Heikkinen | Chief Executive Officer | 0 companies |
| Risto Olavi Ekholm | Deputy auditor | 0 companies |
| Markku Olavi Koskela | Deputy auditor | 0 companies |
| Arno Kalervo Sipponen | Chairperson | 0 companies |
| Lauri Ilmari Sipponen | Board of Directors | 0 companies |
| Conny Juhani Virtanen Friman | Board of Directors | 0 companies |
| Taika Tuuli Sipponen | Board of Directors | 0 companies |
| Nils Erik Gustaf Flodin | Chairperson | 0 companies |
| Immo Ilari Sipponen | Board of Directors | 0 companies |
| Mathias Tomas Saladin Grunér | Board of Directors | 0 companies |
| Pentti Ilmari Sipponen | Board of Directors | 0 companies |
| Carl Sebastian Christofer Schröder | Board of Directors | 0 companies |